|
Depression is a variety of causes as the main symptoms of depression, a mood disorder or affective disorder, clinically depressed state of mind, slow thinking, will hypoactivity, cognitive impairment, and somatic symptoms. Studies have shown that the lifetime prevalence of depression was 5.2% to 16.2%, and speculated on the prevalence of depression in mainland China, according to World Health Organization data, may be in the 7% to 8%. Drug treatment is to alleviate the symptoms of depression in patients with an effective means of improving the quality of life of patients. Escitalopram is the S-isomer metabolite clinically proven efficacy of selective 5 - serotonin re-uptake inhibitors (SSRIs) racemic citalopram. 2002, the FDA approved for marketing, the introduction of China in 2006. Foreign studies have shown the efficacy of escitalopram better than or similar to other SSRIs, mild side effects. Fewer domestic Clinical data on escitalopram in this study paroxetine control, comparing escitalopram efficacy and safety, and to provide a reference for clinical. Objective To investigate the efficacy and safety of escitalopram depression patients. Methods 80 patients in line with the CCMD-3 depressive episodes outpatient and inpatient escitalopram group and the paroxetine group were randomly divided into the escitalopram dose 10 to 20 mg / d, paroxetine 20 ~ 40mg / d, Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) to evaluate the efficacy, side effects scale (TESS) assessment of adverse reactions and laboratory tests and security. Observation time period of six weeks. The input SPSS data collected database application SPSS10.0 statistical software for analysis, according to the nature of the information. Results (1) escitalopram and paroxetine groups at the end of treatment, the HAMD and HAMA total score from baseline were significantly lower escitalopram group t values ??were 18.6,16.5, paroxetine 19.2 , 17.6, compare the differences and enrolled very significant (P <0.01). (2) between the two groups at the the treatment first 1,2,4,6 weekend HAMD the HAMA total average difference was not statistically significant (P> 0.05). HAMD and HAMA factor analysis found a significant difference (P> 0.05), nor in all the assessment points. (3) at the end of treatment, escitalopram group efficiency of 75.7%, the cure rate was 54.1% in the paroxetine group efficiency of 80.6%, 61.1% cure rate, no significant difference between the two groups (P> 0.05) . (4) adverse reactions escitalopram group total incidence of 16.2% in the paroxetine group was 33.3%, the difference was significant (P <0.05). Two groups expulsion rate and dropout rate of 5.3% and 7.9%, respectively, and no significant difference. Conclusions Escitalopram in the treatment of patients with depression are safe and effective, the efficacy of paroxetine Similar lighter side effects and better compliance.
|